Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors. 2019

Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
Hutchison MediPharma Limited , Building 4, 720 Cai Lun Road, Zhangjiang Hi-Tech Park , Shanghai 201203 , China.

An electronic density model was developed and used to identify a novel pyrrolotriazinone replacement for a quinazolinone, a commonly used moiety to impart selectivity in inhibitors for PI3Kγ and PI3Kδ. Guided by molecular docking, this new specificity piece was then linked to the hinge-binding region of the inhibitor using a novel cyclic moiety. Further structure-activity relationship optimization around the hinge region led to the discovery of candidate 26, a highly potent and selective PI3Kγ-PI3Kδ dual inhibitor with favorable drug metabolism and pharmacokinetic properties in preclinical species.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000067996 RAW 264.7 Cells A transformed macrophage cell line isolated from ASCITES of mice infected with ABELSON MURINE LEUKEMIA VIRUS. RAW 264.7 Cell Line,264.7 Cell, RAW,264.7 Cells, RAW,Cell, RAW 264.7,Cells, RAW 264.7,RAW 264.7 Cell
D000078722 PC-3 Cells An epithelial cell line initiated from a human bone metastasis of a grade IV prostatic ADENOCARCINOMA. Human Prostatic Carcinoma Cell Line PC3,PC-3 (Human Prostatic Carcinoma) Cell Line,PC-3 Cell Line,PC3 Cell Line,PC3 Cells,Cell Line, PC-3,Cell Line, PC3,Cells, PC-3,Cells, PC3,Line, PC-3 Cell,PC 3 Cell Line,PC 3 Cells,PC-3 Cell
D000081082 Phosphoinositide-3 Kinase Inhibitors Agents that inhibit PHOSPHOINOSITIDE-3 KINASE activity. Phosphoinositide-3 Kinase Inhibitor,Inhibitor, Phosphoinositide-3 Kinase,Inhibitors, Phosphoinositide-3 Kinase,Kinase Inhibitor, Phosphoinositide-3,Kinase Inhibitors, Phosphoinositide-3,Phosphoinositide 3 Kinase Inhibitor,Phosphoinositide 3 Kinase Inhibitors
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001169 Arthritis, Experimental ARTHRITIS that is induced in experimental animals. Immunological methods and infectious agents can be used to develop experimental arthritis models. These methods include injections of stimulators of the immune response, such as an adjuvant (ADJUVANTS, IMMUNOLOGIC) or COLLAGEN. Adjuvant Arthritis,Arthritis, Adjuvant-Induced,Arthritis, Collagen-Induced,Arthritis, Adjuvant,Collagen Arthritis,Arthritides, Collagen,Arthritis, Collagen,Collagen Arthritides,Collagen-Induced Arthritides,Collagen-Induced Arthritis
D017207 Rats, Sprague-Dawley A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company. Holtzman Rat,Rats, Holtzman,Sprague-Dawley Rat,Rats, Sprague Dawley,Holtzman Rats,Rat, Holtzman,Rat, Sprague-Dawley,Sprague Dawley Rat,Sprague Dawley Rats,Sprague-Dawley Rats
D017208 Rats, Wistar A strain of albino rat developed at the Wistar Institute that has spread widely at other institutions. This has markedly diluted the original strain. Wistar Rat,Rat, Wistar,Wistar Rats

Related Publications

Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
October 2020, Journal of medicinal chemistry,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
July 2022, Journal of medicinal chemistry,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
January 2020, Bioorganic & medicinal chemistry letters,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
July 2017, Bioorganic & medicinal chemistry letters,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
February 2017, Bioorganic & medicinal chemistry letters,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
November 2020, ACS medicinal chemistry letters,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
September 2023, Bioorganic chemistry,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
May 2018, European journal of medicinal chemistry,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
January 2016, Journal of medicinal chemistry,
Hong Jia, and Guangxiu Dai, and Weiguo Su, and Kun Xiao, and Jianyang Weng, and Zhulin Zhang, and Qing Wang, and Tianhai Yuan, and Fuying Shi, and Zheng Zhang, and Wei Chen, and Yang Sai, and Jian Wang, and Xiong Li, and Yu Cai, and Jun Yu, and Ping Ren, and Jennifer Venable, and Tadimeti Rao, and James P Edwards, and Scott D Bembenek
January 2021, ACS medicinal chemistry letters,
Copied contents to your clipboard!